Disease-specific quality indicators, guidelines, and outcome measures in vasculitis.

Disease-specific quality indicators, guidelines, and outcome measures in vasculitis.

Measuring quality of care in the anti neutrophil cytoplasm antibody (ANCA) associated vasculitides (AAV) has become more complex, because the introduction of immunosuppressive therapy has resulted in a substantial improvement in survival. Early diagnosis remains a problem, because many patients are...

Bibliografski detalji
Glavni autori:	Mukhtyar, C, Luqmani, R
Format:	Journal article
Jezik:	English
Izdano:	2007

Slični predmeti

Using the Birmingham vasculitis activity score (BVAS) to screen for vasculitis
od: Mukhtyar, C, i dr.
Izdano: (2008)

Eular recommendations for vasculitis
od: Luqmani, R, i dr.
Izdano: (2007)

Cardiovascular outcomes in ANCA associated vasculitis
od: Mukhtyar, C, i dr.
Izdano: (2008)

Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus.
od: Mukhtyar, C, i dr.
Izdano: (2007)

Cardiovascular involvement in primary systemic vasculitis.
od: Mukhtyar, C, i dr.
Izdano: (2009)

Using the Birmingham Vasculitis Activity Score (BVAS) for diagnosing vasculitis
od: Luqmani, R, i dr.
Izdano: (2009)

USING THE BIRMINGHAM VASCULITIS ACTIVITY SCORE (VERSION 3) FOR DIAGNOSING VASCULITIS
od: Mukhtyar, C, i dr.
Izdano: (2009)

Cardiovascular outcomes in antineutrophil cytoplasm antibody associated vasculitis (AAV)
od: Mukhtyar, C, i dr.
Izdano: (2008)

Outpatient assessment of systemic vasculitis.
od: Nataraja, A, i dr.
Izdano: (2007)

Outcome measures in ANCA-associated vasculitis.
od: Suppiah, R, i dr.
Izdano: (2010)

The role of biologic therapies in the management of systemic vasculitis.
od: Chan, A, i dr.
Izdano: (2006)

Current evidence of factors influencing remission, relapse, renal failure and mortality in patients with systemic vasculitis. A systematic review for the EULAR systemic vasculitis task force
od: Mukhtyar, C, i dr.
Izdano: (2007)

Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis.
od: Mukhtyar, C, i dr.
Izdano: (2006)

The vasculitis damage index as a surrogate outcome measure in systemic vasculitis.
od: McRorie, E, i dr.
Izdano: (1997)

Outcome in systemic vasculitis.
od: Luqmani, R, i dr.
Izdano: (1998)

Factors influencing remission, relapse, renal failure and mortality in patients with systemic vasculitis
od: Luqmani, R, i dr.
Izdano: (2007)

Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis.
od: Walsh, M, i dr.
Izdano: (2011)

Validation of the Birmingham Vasculitis Activity Score (Version 3)
od: Mukhtyar, C, i dr.
Izdano: (2009)

Disease assessment in systemic vasculitis
od: Luqmani, R
Izdano: (2004)

THE PROGNOSTIC VALUE OF THE BIRMINGHAM VASCULITIS ACTIVITY SCORE AND THE VASCULITIS DAMAGE INDEX IN ANCA-ASSOCIATED VASCULITIS
od: Suppiah, R, i dr.
Izdano: (2011)

Outcome in small-vessel systemic vasculitis.
od: Luqmani, R, i dr.
Izdano: (2006)

Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure
od: Robson, J, i dr.
Izdano: (2018)

Evaluation of vasculitis disease activity in Europe.
od: Luqmani, R
Izdano: (2001)

Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure
od: Robson JC, i dr.
Izdano: (2018-01-01)

Current status of outcome measure development in vasculitis.
od: Merkel, P, i dr.
Izdano: (2014)

Validation of a new version of the Birmingbam vasculitis activity score
od: Mukhtyar, C, i dr.
Izdano: (2008)

Vasculitis: an update.
od: Luqmani, R
Izdano: (2014)

Vasculitis: an update.
od: Luqmani, R
Izdano: (2014)

A disease-specific patient-reported outcome for anti-neutrophil cytoplasmic antibody–associated vasculitis: scale structure and measurement properties of the anti-neutrophil cytoplasmic antibody-associated vasculitis patient-reported outcome measure
od: Robson, J, i dr.
Izdano: (2017)

Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index.
od: Suppiah, R, i dr.
Izdano: (2011)

Measurement of damage in systemic vasculitis: A comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index
od: Suppiah, R, i dr.
Izdano: (2010)

Discontinuation of therapies in vasculitis.
od: Luqmani, R
Izdano: (2013)

Discontinuation of therapies in vasculitis.
od: Luqmani, R
Izdano: (2013)

Discontinuation of therapies in vasculitis.
od: Luqmani, R
Izdano: (2013)

CLASSIFICATION AND DIAGNOSIS OF VASCULITIS
od: Luqmani, R
Izdano: (2012)

A disease-specific patient-reported outcome for ANCA associated vasculitis: scale structure and measurement properties of the AAV- PRO
od: Robson, J, i dr.
Izdano: (2017)

Pharmacotherapy of vasculitis.
od: Chan, M, i dr.
Izdano: (2009)

Scale Structure and Measurement Properties of a Disease Specific Patient-Reported Outcome for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
od: Robson, J, i dr.
Izdano: (2016)

MEASUREMENT OF DAMAGE IN SYSTEMIC VASCULITIS: A COMPARISON OF THE VASCULITIS DAMAGE INDEX (VDI) WITH THE COMBINED DAMAGE ASSESSMENT INDEX (CDA)
od: Suppiah, R, i dr.
Izdano: (2010)

276 The short-term damage burden in vasculitis and vasculitis mimics as measured by the vasculitis damage index
od: Floris, A, i dr.
Izdano: (2016)